September 3 (Thu)


Satellite Symposium 1
Servier  boryung
Future insight for the management of pancreatic and biliary tract cancers
  1. 1.Optimal continuum of care for metastatic pancreatic adenocarcinoma
  2. 2.Individualizing gemcitabine-based regimens in cholangiocarcinoma
  3. 3.Liposomal irinotecan in metastatic pancreatic cancer: Asian and Korean experiences


Satellite Symposium 2
The current and future challenges: Good luck does not always repeat
  1. 1.Turning hope into reality: We dream for a better tomorrow with Pembrolizumab (1L NSCLC)
  2. 2.Everything comes to those who challenge: What is the best regimen for 1L R/M HNSCC patients?
Satellite Symposium 3
The beginning of immunotherapy journey in breast cancer
  1. 1.IMpassion 130: The first immune checkpoint inhibitor for 1L metastatic triple negative breast cancer (mTNBC) patient
  2. 2.Overview of current biomarkers in metastatic TNBC
Satellite Symposium 4
Lenvatinib treatment in first line uHCC and subsequent treatments
  1. 1.Overseas experience on subsequent treatment after 1st Line Lenvima in uHCC
  2. 2.Korean real-world experience of 1st-line Lenvima® in advanced hepatocellular carcinoma


Satellite Symposium 5
Importance of bone health management in palliative setting
  1. 1.Integrated bone health management in prostate cancer
  2. 2.Bone health management in AI-treating breast cancer


Satellite Symposium 6
Changing lives with breakthrough cancer pain management
  1. 1.Patient-centred treatment strategies for breakthrough cancer pain
  2. 2.Fentanyl pectin nasal spray (PecFent): A novel intranasal delivery method for breakthrough cancer pain management


Satellite Symposium 7
What is being considered for continuum of care in metastatic colorectal cancer?
  1. 1.Biomarker driven 2nd line treatment for patients with mCRC: Insights in Biomarker
  2. 2.Choosing anti-VEGF agents in 2nd line treatment for mCRC: Korean experience

September 4 (Fri)


Satellite Symposium 8
Broaden horizon of new PD-L1 inhibitor, Avelumab
Broaden horizon of new PD-L1 inhibitor, Avelumab


Satellite Symposium 9
New perspectives for treatment naïve patients with EGFR+ NSCLC
  1. 1.Treatment for EGFR+ NSCLC: Where are we now? And “the new role of Dacomitinib”
  2. 2.Optimal treatment sequence in EGFR mutation positive NSCLC


Satellite Symposium 10
Continuing Advances in metastatic Breast Cancer: How to make optimal treatment decision for metastatic breast cancer patients
  1. 1.Continuing advances in metastatic breast cancer: Clinical overview of Abemaciclib
  2. 2.Role of prognostic factor in treatment choice for HR+, HER2- metastatic breast cancer patients
Satellite Symposium 11
Treatment options for patients with ALK+ NSCLC: How is the paradigm changing?
  1. 1.Long-term survival for patients with ALK+ NSCLC: An achievable aim?
  2. 2.New Standards of Care in post crizotinib ALK+NSCLC: Roles of brigatinib in optimal sequential treatments


Satellite Symposium 12
Ever forward with cancer immunotherapy: the progress so far and new frontiers
  1. 1.Optimal Therapeutic Strategies for Esophageal cancer
  2. 2.Big Journey of Immunotherapy for NSCLC in Korea
Satellite Symposium 13
From concept to practice - new era of precision medicine
Larotrecitinb, “The REAL DRUG” for TRK fusion cancer patients


Satellite Symposium 14
Daewoong  Samsung Bioepis
Building confidence in Biosimilars: From data to patient